The Ex-Segway Team Building a Smart ATV Europe Isn't Ready For + more | China Tech Signals

26 Mar 2026

China Tech Signals

Smart Mobility / Consumer Hardware

The Ex-Segway Team Building a Smart ATV Europe Isn't Ready For

A Chinese hardware team with Segway pedigree is building a software-rich electric ATV — and Hillhouse-tier capital is lining up behind it. Europe's off-road market is growing fast, electrifying faster, and largely unprepared for what's coming down the trail.

EV & Industrial Infrastructure

2,000 Chinese Workers Are Building the Gigafactory EU Rules Are Meant to Protect

Brussels proposed its Industrial Accelerator Act on 4 March 2026, requiring at least 50% EU workers for strategic investments. In Figueruelas, Spain, 2,000 Chinese workers are already on-site building a €4.1bn ($4.8bn) CATL-Stellantis battery gigafactory — with more than €300m in EU funding behind it. The dependency Europe is debating in policy papers is already being poured into concrete in Aragon.

Consumer Tech & IP

Papergames Is Physicalizing Its Gaming IPs — European Character Franchises Face a New Front

Chinese gaming firm Papergames has begun recruiting for AI robotics roles, signalling its intent to turn beloved virtual companions from its hit titles into physical, emotionally responsive robots. For European gaming and entertainment IP holders, this isn't a distant curiosity — it's a preview of what vertically integrated IP-to-hardware pipelines look like when they reach your market. The window to respond is narrowing.

Autonomous Vehicles / Smart Mobility

DJI's Perception DNA Is Now Inside Your OEM's Supply Chain

ZYT, the autonomous-driving spinout born inside DJI, is raising $280 million at a $1.74 billion valuation and targeting a Hong Kong IPO. European OEMs rationalising their ADAS supply chains should treat this as a direct competitive signal — not a distant China story.

biotechhealthtech

QL Biopharm Raises ¥500M+ Series C to Lead Monthly GLP-1 Race

Beijing-based QL Biopharm has closed a Series C round of over RMB 500 million (~$70 million), led by OrbiMed, to advance a pipeline of long-acting and oral peptide therapies for chronic metabolic diseases. Its lead asset, a once-monthly GLP-1 receptor agonist, is in Phase 3 trials and could become the world's first monthly GLP-1 peptide approved for market.